Continuous Manufacturing of Peptides Could Speed Up Development, Reduce Costs & Improve Quality

摘要

Despite the many obvious clinical advantages – safety and selectivity, leading to superior safety and efficacy - and the increasing number of commercial successes, the full potential of peptide therapeutics has yet to be unleashed. Estimated to exceed $46 billion by the end of 2025, the global therapeutics market has attracted the attention of key players, such as Eli Lilly, Novo Nordisk, Pfizer, Takeda, and Amgen. One of the barriers to both development and production has been the high cost of the current state of the art batch manufacturing processes. A new manufacturing process lowering the cost and speeding up their development whilst allowing for superior quality could give the development of therapeutic peptides even more momentum.